|
|
|
|
|
|
|
|
|
|
|
|
|
13.11.25 - 18:51
|
Poxel Reports Revenue for the Third Quarter 2025 (Business Wire)
|
|
|
TWYMEEG® sales continue to grow in Japan, up 5% in the last quarter (July-September) compared to the previous quarter and up 40% compared to the third quarter of 2024
Gross TWYMEEG® for Sumitomo Pharma amounted to JPY 5 billion for the first half ended September 30, supporting its full-year forecast of JPY 11.2 billion for the fiscal year ending March 31, 20261, which would represent a 47% increase compared to fiscal year 2024 sales
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports its revenue for the quarter ended September 30, 2025, and for the first nine months of the fiscal year.
Nicolas Trouche, Chief Executive Officer of Poxel, states: “Dear shareholders, as you know, Poxel is in a very difficult situation due t...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.06.25 - 12:48
|
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo′s Canadian Portfolio (GlobeNewswire EN)
|
|
|
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA's affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue....
|
|
|
13.05.25 - 07:36
|
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update (Business Wire)
|
|
|
TWYMEEG® consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3
Sumitomo Pharma forecast for TWYMEEG®'s FY 20254 of JPY 11.2 billion (EUR 69,4 million2), representing a 47% increase over FY 2024 sales
In FY2024, Poxel started receiving 10% royalties on TWYMEEG® net sales, and from FY2025 5 anticipates receiving escalating double-digit royalties and additional sales-based payments upon achievement of contractual sales thresholds
Regulatory approval on April 8, 2025, by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enabling Sumitomo Pharma to immediately start promoting the use of TWYMEEG® (Imeglimin) in type 2 diabetic patients with moderate to severe renal impairment
Ongoing discussions with 1/ creditors to ensure continuity of the Company's operations and 2/ potential partners for the development of pipeline products
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL S...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
